Published in:
01-05-2014 | Erratum
Erratum to: Current and future therapies for hepatitis C virus infection: from viral proteins to host targets
Published in: Archives of Virology | Issue 5/2014
Login to get accessExcerpt
Unfortunately, Table 1 was incorrectly published in the original article. The corrected table is given below:
Table 1
Drugs against hepatitis C virus infection
|
Company
|
Drug
|
Mechanism of action
|
Stage of clinical development
|
|---|---|---|---|
|
Biotron Limited
|
BIT225
|
Inhibits HCV P7 protein
|
Completed phase IIa
|
|
Roche
|
Danoprevir
|
Inhibits NS3 protein
|
Phase II
|
|
Merck
|
Vaniprevir
|
Inhibits NS3 protein
|
Phase II
|
|
Merck
|
Boceprevir
|
Inhibits NS3 protein
|
APPROVED
|
|
Vertex
|
Telaprevir
|
Inhibits NS3 protein
|
APPROVED
|
|
Tibotec/Medivir/J&J
|
TMC-435
|
Inhibits NS3 protein
|
Phase III
|
|
Boehringer Ingelheim
|
BI 201335
|
Inhibits NS3 protein
|
Phase III
|
|
Achillion Pharmaceuticals/Gilead
|
ACH-806
|
NS4A antagonist
|
Phase 1b/2
|
|
Eiger Biopharmaceuticals
|
Clemizole hydrochloride
|
Inhibitor of NS4B:RNA
|
Phase 1b
|
|
MedChem Express
|
Anguizole
|
Inhibitor of HCV RNA replication
|
Phase 1b
|
|
Bristol-Myers Squibb
|
BMS-790052
|
NS5A inhibitor
|
Phase III
|
|
Bristol-Myers Squibb
|
BMS-824
|
NS5A inhibitor
|
Phase II
|
|
Gilead Sciences
|
GS-5885
|
NS5A inhibitor
|
Phase II
|
|
GlaxoSmithKline
|
GSK2336805
|
NS5A inhibitor
|
Phase II
|
|
Presidio Pharmaceuticals
|
PPI-668
|
NS5A inhibitor
|
Phase II
|
|
Pharmasset
|
PSI-7851
|
NS5B inhibitor
|
Phase II
|
|
Abbott
|
ABT-072
|
Non-nucleoside polymerase inhibitor
|
Phase II
|
|
Abbott
|
ABT-333
|
Non-nucleoside polymerase inhibitor
|
Phase III
|
|
Santaris Pharma
|
SPC3649
|
Lock nucleic acid mRNA122 inhibitor
|
Phase 1
|
|
Human Genome Sciences
|
Zalbin
|
Immunomodulator
|
Phase III
|
|
Novartis/Debiopharm
|
Debio 025
|
Cyclophilin inhibitor
|
Phase III
|
|
SciClone Pharma/Sigma-Tau
|
Zadaxin Thymalfasin
|
Immunomodulator
|
Phase III
|